Research programme: calcium channel and sodium channel antagonists - Anabios CorporationAlternative Names: N-type CCB; N/T-Type CCB; NP-A; T-type CCB; Z-212
Latest Information Update: 01 Aug 2016
At a glance
- Originator Neuromed Pharmaceuticals
- Developer Hydra Biosciences; Neuromed Pharmaceuticals
- Class Analgesics; Small molecules
- Mechanism of Action N type calcium channel antagonists; Sodium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain